Target intelligence / Profile preview

T cell receptor beta-chain constant region 2 (TRBC2)

Target
TRBC2
Molecular classification
Receptor (membrane receptor), Immunoglobulin superfamily, T cell receptor subunit
01

Overview

T cell receptor beta-chain constant region 2 is one of two nearly identical constant region genes (TRBC1, TRBC2) within the human TCR beta-chain locus on chromosome 7[1][9]. The TCR beta chain is a critical component of the T cell receptor complex, which is a membrane-bound heterodimeric protein involved in recognizing antigen peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells[3][5][7]. The constant region 2, like constant region 1, helps to form the structural backbone that stabilizes the beta chain and anchors it within the T cell membrane, facilitating signal transduction when the TCR is engaged by peptide-MHC[1][3][5]. The presence of two near-identical constant region genes likely arises from an ancient gene duplication event[1][9]. TRBC2 is occasionally targeted in immunophenotyping assays to track clonal T cells or distinguish populations in research or diagnostics. While not a common direct drug target, its integrity and proper expression are essential for normal TCR function and therefore for any therapeutic applications involving engineered TCRs.

Other names
TRBC2TCR Cβ2TCR beta constant region 2Constant region 2 of TCR-beta chainCβ2
02

Mechanism of action

TCR engineering: Transfer of TCRs with defined specificity into patients’ T cells to target cancer antigen peptides presented on MHCs, depending on the proper structure/function of TCR alpha and beta chains (including constant region 2). No direct ligand/drug with a defined mechanism of action specific for the beta-chain constant region 2.

03

Biological functions

Antigen recognition (forms part of the TCR complex that recognizes peptide-MHC complexes)Signal transduction (via the TCR/CD3 complex)Adaptive immune response mediationT cell differentiation and activation
04

Disease associations

Cancer (targeted by TCR-engineered T cell therapies)Infection (involved in immune responses to pathogens)Autoimmune disease (aberrant TCR function linked to autoimmunity)Other immune dysregulation disorders
05

Safety considerations

On-target, off-tumor toxicity—TCR-based therapies can cause immune-related adverse effects due to cross-reactivity.Potential for TCR mispairing, which may create unintended specificities and pose safety risks in TCR-engineered cell therapies.Immunogenicity—engineered TCRs may trigger immune responses against modified T cells.Lack of specificity for the constant region; most adverse effects relate to the broader TCR/CD3 complex or engineered therapy, not to Cβ2 uniquely.
06

Interacting drugs

No small molecule or antibody drugs directly interact with the constant region 2 of the TCR beta chain in approved or late-stage clinical use as of mid-2024. However, TCR-engineered T cells (TCR-T therapies) rely on manipulation or recognition of the TCR beta chain (including both constant regions). Some immune checkpoint modulators affect signaling downstream of the TCR/CD3 complex.
07

Biomarkers

TRBC2 and TRBC1 can be used in flow cytometry to assess T cell clonality, distinguish between T cell clones, or monitor minimal residual disease in T cell neoplasms (e.g., TRBC1/2 antibodies for flow cytometry in T-PLL, T-ALL).

Beyond the preview

Go deeper on T cell receptor beta-chain constant region 2 (TRBC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor beta-chain constant region 2 (TRBC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call